UCSF School of Pharmacy

Apple Tree Partners Recruits Noted Biotech Entrepreneur and Computer-Aided Drug Design Pioneer Matthew P. Jacobson, Ph.D., as New Venture Partner

Retrieved on: 
Tuesday, July 11, 2023
Columbia University, UCSF School of Pharmacy, University of Oxford, PLOS Computational Biology, University, Therapy, Education, Emeritus, NSF, National Science Foundation, ATP, Stanford University, Partner (business rank), Research, MIT, Science, Biochemistry, UCSF School of Medicine, Structure, Entrepreneurship, Parkinson's disease, Publication, Investment, UCSF, Medicinal chemistry, Chemistry, Sickle cell disease, Knowledge, USCF, Ecosystem, FDA, ALS, Jacobson, Graduate Group in the Art and Archaeology of the Mediterranean World, Pfizer, Pharmaceutical industry, Biophysics

NEW YORK and SOUTH SAN FRANCISCO, Calif., July 11, 2023 /PRNewswire/ -- Apple Tree Partners (ATP), a leader in life sciences venture capital, announced today that Matthew P. Jacobson, Ph.D., serial biotech entrepreneur and Professor Emeritus in the Department of Pharmaceutical Chemistry at University of California San Francisco (UCSF), has joined ATP as a venture partner. In this role, he will identify opportunities for new life sciences investments and company creation and provide strategic expertise to ATP's portfolio companies. He will be based in ATP's South San Francisco office.

Key Points: 
  • In this role, he will identify opportunities for new life sciences investments and company creation and provide strategic expertise to ATP's portfolio companies.
  • Dr. Jacobson's research interests are in the areas of computational biophysics and computer-aided drug design; he is the author of more than 200 publications and several patents.
  • He presently devotes most of his time to biotech entrepreneurship and has co-founded six successful biotech companies in the past dozen years.
  • "We have enjoyed a productive working relationship with Matt for several years, and we are delighted to formally welcome him to ATP as a venture partner and scientific advisor," said Seth Harrison, M.D., Apple Tree Partners' founder and Managing Partner.

Apple Tree Partners Recruits Noted Biotech Entrepreneur and Computer-Aided Drug Design Pioneer Matthew P. Jacobson, Ph.D., as New Venture Partner

Retrieved on: 
Tuesday, July 11, 2023
Columbia University, UCSF School of Pharmacy, University of Oxford, PLOS Computational Biology, University, Therapy, Emeritus, Education, NSF, National Science Foundation, ATP, Stanford University, Partner (business rank), Research, MIT, Science, Biochemistry, UCSF School of Medicine, Structure, Entrepreneurship, Parkinson's disease, Publication, Investment, UCSF, Medicinal chemistry, Chemistry, Sickle cell disease, Knowledge, USCF, Ecosystem, FDA, ALS, Jacobson, Graduate Group in the Art and Archaeology of the Mediterranean World, Pfizer, Pharmaceutical industry, Biophysics

NEW YORK and SOUTH SAN FRANCISCO, Calif., July 11, 2023 /PRNewswire/ -- Apple Tree Partners (ATP), a leader in life sciences venture capital, announced today that Matthew P. Jacobson, Ph.D., serial biotech entrepreneur and Professor Emeritus in the Department of Pharmaceutical Chemistry at University of California San Francisco (UCSF), has joined ATP as a venture partner. In this role, he will identify opportunities for new life sciences investments and company creation and provide strategic expertise to ATP's portfolio companies. He will be based in ATP's South San Francisco office.

Key Points: 
  • In this role, he will identify opportunities for new life sciences investments and company creation and provide strategic expertise to ATP's portfolio companies.
  • Dr. Jacobson's research interests are in the areas of computational biophysics and computer-aided drug design; he is the author of more than 200 publications and several patents.
  • He presently devotes most of his time to biotech entrepreneurship and has co-founded six successful biotech companies in the past dozen years.
  • "We have enjoyed a productive working relationship with Matt for several years, and we are delighted to formally welcome him to ATP as a venture partner and scientific advisor," said Seth Harrison, M.D., Apple Tree Partners' founder and Managing Partner.

eFFECTOR Therapeutics Doses First Patient in Second Cohort of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19

Retrieved on: 
Wednesday, September 14, 2022
Hospital, Receptor tyrosine kinase, Plasma, EIF4E, Safety, Stri Parva, COVID-19, UCSF School of Pharmacy, University of California, San Francisco, Effector, RNA transfection, Orthornavirae, Virus, NSCLC, EIF4A, QBI, Severe acute respiratory syndrome coronavirus 2, DARPA, Review, Private Securities Litigation Reform Act, Therapy, COVID, U.S. Securities and Exchange Commission, STRI, Government, ER, Patient, Test, University of California, Cancer, Survival, Disease, Clinical trial, UCSF School of Medicine, Protein, Biology, Solution, NASDAQ, SAN, KRAS, RNA, MNK, Research, Security (finance), GLOBE, Escape Room, Pembrolizumab, University, Genome, CDK, 4F, Pfizer, Death, Pharmaceutical industry, Vaccine, Pharmacy, KICKSTART, Nature

SAN DIEGO and REDWOOD CITY, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced it has dosed the first patient in the second cohort of its Phase 1b clinical trial of zotatifin in non-hospitalized adults with confirmed COVID-19 infection. The study is a double-blind, randomized, placebo-controlled trial evaluating the safety and antiviral activity of a single dose of zotatifin and is being conducted in collaboration with the Quantitative Biosciences Institute (QBI) at the University of California, San Francisco, under a $5 million cooperative agreement sponsored by the Defense Advanced Research Projects Agency.

Key Points: 
  • Dose escalation to the second cohort comes after the positive recommendation of the independent data safety monitoring board upon review of safety data from the first dose cohort.
  • The completed cohort also included the first subjects dosed with a sub-cutaneous formulation of zotatifin and preliminary analysis demonstrated equivalent plasma drug levels compared to IV delivery.
  • Achieving equivalent drug levels when zotatifin was delivered by the sub-cutaneous route provides an opportunity for convenient dosing in both the COVID and cancer settings.
  • As such, zotatifin may have a higher barrier to viral mutational escape than therapies that target components of the virus itself.

HOSP Expands Board, Adds Members And Partners

Retrieved on: 
Wednesday, June 8, 2022
General Health, Pharmaceutical, Health, Other Health, Association, Baystate Health, Board of directors, Director, UCSF School of Pharmacy, Record, Faculty of Pharmacy, University of Lisbon, Nebraska Medicine, Therapy, HOSP, UCSF School of Medicine, Industry, Board, Health system, Pharmacy and Therapeutics, Health, Hospital, Pharmacy

The Health System Owned Specialty Pharmacy Alliance ( HOSP ), the non-profit trade association dedicated to integrated specialty pharmacies, expanded its Board of Directors while accepting six new members and five partners to the organization last month.

Key Points: 
  • The Health System Owned Specialty Pharmacy Alliance ( HOSP ), the non-profit trade association dedicated to integrated specialty pharmacies, expanded its Board of Directors while accepting six new members and five partners to the organization last month.
  • Desi Kotis, Pharm.D FASHP, chief pharmacy executive, UCSF Health and associate dean and clinical professor, UCSF School of Pharmacy and Kyle Skiermont, vice president, Pharmacy and Therapeutics, Nebraska Medicine, College of Pharmacy University of Nebraska Medical Center, accepted seats on the Board of Directors increasing the Board total to 10 members.
  • Desi and Kyle bring vast industry expertise and long-standing successful track records in leadership positions to the Board in support of HOSPs mission, said Gary Kerr, President of the HOSP Board of Directors and Chief Pharmacy Officer at Baystate Health.
  • These new members and partners come from a variety of areas in the industry but are all focused on one thing: improving patient outcomes with integrated specialty pharmacies.